2,3-butanedione monoxime
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 17, 2018 (NCT03634085)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Sodium/calcium exchanger 1INHIBITOR
SLC8A1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 2,3-butanedione monoxime
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03634085 | Phase 1 | May 17, 2018 | Quotient, Venn Life Sciences |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Quotient | For profit | 1 | 1 | 1 | 2018 |
| Venn Life Sciences | For profit | 1 | 0 | 1 | 2018 |
2 organizations
Page 1 / 1